Pharmacokinetic study and limited sampling strategy of cyclosporine in Japanese heart transplant recipients

Circulation Journal

Volumn 70, Issue 10, 2006, Pages 1307-1311

  Wada, Kyoichi ^a   Takada, Mitsutaka ^b   Ueda, Takashi ^c   Ochi, Hiroyuki ^a   Morishita, Hideki ^a   Hanatani, Akihisa ^a   Nakatani, Takeshi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

C 2 monitoring; Cyclosporine; Heart; Pharmacokinetics; Transplantation

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADOLESCENT; ADULT; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; JAPAN; KIDNEY FUNCTION TEST; MALE; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; SAMPLING; STATISTICAL SIGNIFICANCE; SURGICAL PATIENT;

ADOLESCENT; ADULT; AREA UNDER CURVE; CYCLOSPORINE; DRUG MONITORING; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; MIDDLE AGED; PHARMACOKINETICS; TIME FACTORS;

EID: 33748995134     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.1307     Document Type: Article

References (21)

1. Cantarovich M, Giannetti N, Cecere R. Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction. Clin Transplant 2003; 17: 144-150.
2. Belitsky P, Dunn S, Johnston A, Levy G. Impact of absorption pro-filing on efficacy and safety of cyclosporin therapy in transplant recipients. Clin Pharmacokinet 2000; 39: 117-125.
3. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55-62.
4. Belitsky P, Levy GA, Johnston A. Neoral absorption profiling: An evolution in effectiveness. Transplant Proc 2000; 32: 45S-52S.
5. Cantarovich M, Elstein E, de Varennes B, Barkun JS. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 1999; 68: 1839-1842.
6. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 2001; 34: 9-16.
7. Cooney GF, Johnston A. Neoral C-2 monitoring in cardiac transplant patients. Transplant Proc 2001; 33: 1572-1575.
8. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R. Twohour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998; 12: 243-249.
9. Delgado DH, Rao V, Hamel J, Miriuka S, Cusimano RJ, Ross HJ. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: Improvement in clinical outcomes. J Heart Lung Transplant 2005; 24: 1343-1346.
10. Chou NK, Chen RJ, Ko WJ, Lin HL, Yu SY, Chen YS, et al. Cyclosporine C2 monitoring is superior to C0 in predicting acute cellular rejection in heart transplant recipients in Taiwan. Transplant Proc 2004; 36: 2393-2395.
11. Batiuk TD, Pazderka F, Enns J, DeCastro L, Halloran PF. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. Clin Invest 1995; 96: 1254-1260.
12. Sindhi R, LaVia MF, Paulling E, McMichael J, Burckart G, Shaw S, et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen. Transplantation 2000; 69: 432-436.
13. Barten MJ, Rahmel A, Garbade J, Richter M, Bittner HB, Dhein S, et al. C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients. Transplant Proc 2005; 37: 1360-1361.
14. Aikawa A, Arai K, Tajima E, Kawamura T, Ogiwara H, Sakai K, et al. Cyclosporine Neoral profiling in Japanese renal transplant recipients. Transplant Proc 2001; 33: 3142-3145.
15. Kitamura S, Kurosawa H, Kondo T, Simizu N, Matuda H, Wada H. Heart and Lung Transplantation Protocols. Tokyo: Medical View Japan; 2003.
16. Ray JE, Keogh AM, McLachlan AJ, Akhlaghi F. Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors. J Heart Lung Transplant 2003; 22: 715-722.
17. Arizon del Prado JM, Aumente Rubio MD, Cardenas Aranzana M, Lopez Malo de Molina MD, Segura Saint-Gerons J, Lopez Granados A, et al. New strategies of cyclosporine monitoring in heart transplantation: Initial results. Transplant Proc 2003; 35: 1984-1987.
18. Benowitz NL, Meister W. Pharmacokinetics in patients with cardiac failure. Clin Pharmacokinet 1976; 1: 389-405.
19. Woosley RL, Echt DS, Roden DM. Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. Am J Cardiol 1986; 57: 25B-33B.
20. Kotake T, Takada M, Komamura K, Kamakura S, Miyatake K, Kitakaze M, et al. Heart failure elevates serum levels of cibenzoline in arrhythmic patients. Circ J 2006; 70: 588-592.
21. Ueno K, Tamamura A, Matsumoto K, Komamura K, Kamakura S, Miyatake K, et al. Evaluation of mexiletine clearance in a Japanese population. Ann Pharmacother 2002; 3 241-245.